PFS
TEVA icon

Prospera Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Prospera Financial Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59M Buy
135,418
+953
+0.7% +$31.7K 0.07% 302
2026
Q1 		$4.05M Sell
134,465
-28,781
-18% -$926K 0.07% 310
2025
Q4 		$5.09M Buy
163,246
+96,845
+146% +$2.39M 0.08% 241
2025
Q3 		$1.34M Buy
66,401
+43,456
+189% +$763K 0.02% 584
2025
Q2 		$385K Sell
22,945
-665
-3% -$10.7K 0.01% 1008
2025
Q1 		$363K Buy
23,610
+280
+1% +$5K 0.01% 911
2024
Q4 		$514K Sell
23,330
-18,344
-44% -$334K 0.01% 737
2024
Q3 		$751K Sell
41,674
-13,975
-25% -$245K 0.02% 589
2024
Q2 		$904K Sell
55,649
-20,568
-27% -$317K 0.03% 530
2024
Q1 		$1.08M Buy
76,217
+29,307
+62% +$369K 0.03% 476
2023
Q4 		$490K Sell
46,910
-1,069
-2% -$9.98K 0.02% 672
2023
Q3 		$489K Sell
47,979
-804
-2% -$7.49K 0.02% 620
2023
Q2 		$367K Sell
48,783
-46,988
-49% -$381K 0.01% 709
2023
Q1 		$848K Buy
95,771
+46,298
+94% +$458K 0.03% 472
2022
Q4 		$451K Sell
49,473
-12,337
-20% -$108K 0.02% 563
2022
Q3 		$499K Buy
61,810
+27,197
+79% +$240K 0.03% 520
2022
Q2 		$260K Sell
34,613
-9,491
-22% -$82.7K 0.01% 665
2022
Q1 		$414K Buy
44,104
+16,921
+62% +$141K 0.02% 649
2021
Q4 		$218K Sell
27,183
-29,500
-52% -$266K 0.01% 810
2021
Q3 		$552K Sell
56,683
-5,147
-8% -$48.2K 0.03% 506
2021
Q2 		$612K Sell
61,830
-2,167
-3% -$22.9K 0.03% 478
2021
Q1 		$739K Buy
63,997
+20,288
+46% +$233K 0.04% 403
2020
Q4 		$422K Buy
43,709
+42,335
+3,081% +$406K 0.03% 448
2020
Q3 		$12K Sell
1,374
-43,042
-97% -$455K ﹤0.01% 1072
2020
Q2 		$548K Buy
44,416
+2,100
+5% +$23.8K 0.05% 337
2020
Q1 		$380K Sell
42,316
-18,223
-30% -$187K 0.04% 362
2019
Q4 		$593K Buy
60,539
+19,654
+48% +$175K 0.05% 350
2019
Q3 		$281K Buy
40,885
+5,287
+15% +$40.5K 0.03% 450
2019
Q2 		$333K Buy
+35,598
New +$429K 0.04% 380
2019
Q1 		– Sell
-33,518
Closed -$541K – 433
2018
Q4 		$541K Buy
33,518
+9,152
+38% +$188K 0.11% 182
2018
Q3 		$535K Buy
24,366
+8,321
+52% +$193K 0.1% 203
2018
Q2 		$385K Buy
+16,045
New +$327K 0.05% 290
2017
Q2 		– Sell
-7,642
Closed -$245K – 455
2017
Q1 		$245K Sell
7,642
-144
-2% -$4.91K 0.04% 302
2016
Q4 		$286K Buy
+7,786
New +$311K 0.06% 282

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Prospera Financial Services's TEVA Position: Q2 2026 in Review

Prospera Financial Services increased its Teva Pharmaceuticals (TEVA) stake by 0.71% in Q2 2026, buying an estimated $31.7K and bringing the position to 135,418 shares worth $4.59M. The position accounts for 0.07% of the portfolio, ranked #302.

Prospera Financial Services first reported a position in TEVA in Q4 2016 and has held it in 34 quarters since. The position peaked at $5.09M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Prospera Financial Services held 135,418 shares of Teva Pharmaceuticals worth $4.59M as of Q2 2026.
  • Prospera Financial Services bought 953 Teva Pharmaceuticals shares in Q2 2026, an estimated $31.7K.
  • Teva Pharmaceuticals made up 0.07% of Prospera Financial Services's portfolio in Q2 2026, its #302 holding.
  • Prospera Financial Services first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 34 quarters since.
  • Prospera Financial Services's Teva Pharmaceuticals position peaked at $5.09M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Prospera Financial Services's 13F filing for Q2 2026, filed 15 Jul 2026.